What risk assessment is required before initiating methotrexate therapy?

Risk Stratification Prior to Methotrexate Initiation

Before starting methotrexate, you must obtain baseline laboratory tests (CBC with differential, liver function tests, renal function tests), assess for hepatotoxicity risk factors, perform hepatitis B and C serologic testing, and conduct baseline tuberculosis screening based on individual risk factors. 1, 2

Mandatory Baseline Laboratory Assessment

All patients require the following tests before initiating methotrexate:

• Complete blood count (CBC) with differential and platelet count - to establish baseline hematologic parameters and identify pre-existing cytopenias 1, 2
• Liver function tests (AST, ALT, alkaline phosphatase, albumin, bilirubin) - to detect baseline hepatic abnormalities 1, 2
• Renal function assessment (serum creatinine with calculated creatinine clearance) - critical because methotrexate is renally eliminated and renal impairment significantly increases toxicity risk 3, 2
• Chest X-ray - baseline pulmonary assessment 3, 2

Hepatotoxicity Risk Stratification

Perform noninvasive baseline liver fibrosis assessment before starting methotrexate; baseline liver biopsy is NOT recommended regardless of risk factors. 1

High-Risk Hepatotoxicity Factors to Identify:

• Body mass index ≥40 kg/m² (obesity)
• Diabetes mellitus
• Hyperlipidemia/nonalcoholic fatty liver disease
• Alcohol consumption >1 drink/day for women or >2 drinks/day for men (or binge drinking >7 drinks/week for women, >14 drinks/week for men) 1
• Chronic liver disease (hepatitis B or C)
• Prior exposure to hepatotoxic drugs
• Family history of inheritable liver disease (Wilson disease, hemochromatosis, α-1 antitrypsin deficiency) 1

Baseline Liver Fibrosis Assessment Strategy:

For patients WITHOUT risk factors: Obtain one of the following noninvasive serology tests (FIB-4, Fibrosure, Fibrometer, or Hepascore). If results show no to minimal fibrosis, proceed with methotrexate and repeat annually. 1

For patients WITH risk factors: Obtain noninvasive serology at baseline. If results suggest greater than minimal fibrosis, obtain GI/hepatology consultation and/or vibration-controlled transient elastography before proceeding. Only continue methotrexate if cirrhosis risk is low. 1

Infectious Disease Screening

• Hepatitis B and C serologic testing - mandatory for all patients 1, 2
• Tuberculosis screening (PPD, T-Spot, or QuantiFERON Gold) - should be performed based on individual patient risk factors, as methotrexate can reactivate latent tuberculosis 1

Pulmonary Risk Assessment

For patients over 40 years who smoke or have background respiratory disease (e.g., sarcoidosis), obtain baseline chest X-ray and consider pulmonary function tests. 3 Document any history of pulmonary disease or current respiratory symptoms, as methotrexate-induced pneumonitis, though rare in psoriasis patients, can be fatal. 1

Renal Function Considerations

Calculate creatinine clearance, not just serum creatinine, especially in elderly patients where serum creatinine may overestimate renal function. 2 Patients with creatinine clearance <20 mL/min should avoid methotrexate or receive substantially reduced doses with intensive monitoring. 3 Consider a test dose (2.5-5 mg weekly) in patients with impaired kidney function before escalating to therapeutic doses. 1

Special Population Considerations

Elderly Patients:

Require more cautious assessment due to:

• Declining renal function with age (use creatinine clearance calculation, not serum creatinine alone)
• Decreased folate stores
• Higher frequency of comorbidities
• Increased risk of bone marrow suppression, thrombocytopenia, and pneumonitis 2

Patients with Third-Space Fluid Accumulations:

Evacuate pleural effusions or ascites before starting methotrexate, as drug accumulation in third-space compartments prolongs half-life and causes unexpected toxicity. 2

Risk Factors for Myelosuppression

Identify patients at increased risk for pancytopenia (which can occur after even a single dose):

• Decreased kidney function
• Advanced age
• Low folate stores
• Concomitant medications affecting renal clearance or folate metabolism 1

Contraindications to Identify

Absolute contraindications:

• Pregnancy or breastfeeding
• Cirrhosis
• Significant thrombocytopenia, leukopenia, or anemia
• Creatinine clearance requiring dialysis 1

Relative contraindications requiring careful consideration:

• Concomitant sulfa drugs (can be used with appropriate monitoring)
• Recent nitrous oxide anesthesia exposure 2

Critical Pitfalls to Avoid

1. Do NOT rely on serum creatinine alone in elderly patients - it overestimates renal function; calculate creatinine clearance 2
2. Do NOT skip hepatitis screening - chronic hepatitis B or C significantly increases hepatotoxicity risk 1
3. Do NOT perform routine baseline liver biopsy - this outdated practice has been replaced by noninvasive assessment 1
4. Do NOT overlook metabolic risk factors - obesity, diabetes, and hyperlipidemia are stronger predictors of liver toxicity than cumulative methotrexate dose 1

Documentation Requirements

Before prescribing, ensure patients understand:

• Weekly (not daily) dosing schedule
• Need for effective contraception
• Requirement for regular blood monitoring
• Warning signs of toxicity requiring urgent medical attention (fever, mouth ulcers, unexplained bruising/bleeding, breathlessness, nausea/vomiting) 3